{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T13:51:09Z","timestamp":1765806669623,"version":"build-2065373602"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1016\/j.urolonc.2007.11.004","type":"journal-article","created":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T06:23:50Z","timestamp":1214893430000},"page":"420-425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond"],"prefix":"10.1016","volume":"26","author":[{"given":"Matthew R.","family":"Smith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2007.11.004_bib1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000474311","article-title":"Osteoblast function and osteomalacia in metastatic prostate cancer","volume":"24","author":"Clarke","year":"1993","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2007.11.004_bib2","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1464-410X.1991.tb15260.x","article-title":"Morphometric evidence for bone resorption and replacement in prostate cancer","volume":"68","author":"Clarke","year":"1991","journal-title":"Br J Urol"},{"key":"10.1016\/j.urolonc.2007.11.004_bib3","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2007.11.004_bib4","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1002\/1097-0142(20000615)88:12+<2919::AID-CNCR7>3.0.CO;2-Z","article-title":"Biochemical markers and skeletal metastases","volume":"88","author":"Demers","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2007.11.004_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2007.11.004_bib6","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z","article-title":"Overview of bisphosphonates","volume":"80","author":"Rogers","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2007.11.004_bib7","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A Phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.urolonc.2007.11.004_bib8","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid vs. placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A Phase III, double-blind, randomized trial\u2014Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.11.004_bib9","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2007.11.004_bib10","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2007.11.004_bib11","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2003.05.147","article-title":"Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer","volume":"21","author":"Small","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.11.004_bib12","series-title":"Proceedings of the ASCO","first-page":"177","article-title":"Randomized placebo controlled trial of mitoxantrone\/prednisone and clodronate vs. mitoxantrone\/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study","author":"Ernst","year":"2002"},{"key":"10.1016\/j.urolonc.2007.11.004_bib13","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.urolonc.2007.11.004_bib14","series-title":"Proceedings of the ASCO","first-page":"4511","article-title":"Development of bone metastases from prostate cancer: First results of the MRC PR04 trial (ISCRTN 61384873)","author":"Mason","year":"2004"},{"key":"10.1016\/j.urolonc.2007.11.004_bib15","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.11.004_bib16","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.11.004_bib17","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.2003.08.017","article-title":"American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer","volume":"21","author":"Hillner","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2007.11.004_bib18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2165\/00002018-199921050-00004","article-title":"Comparative tolerability of drug therapies for hypercalcemia of malignancy","volume":"21","author":"Zojer","year":"1999","journal-title":"Drug Saf"},{"key":"10.1016\/j.urolonc.2007.11.004_bib19","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"year":"2007","series-title":"Zoledronic acid prescribing information","key":"10.1016\/j.urolonc.2007.11.004_bib20"},{"key":"10.1016\/j.urolonc.2007.11.004_bib21","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.urolonc.2007.11.004_bib22","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.joms.2003.09.001","article-title":"Avascular necrosis of the jaws: Risk factors in metastatic cancer patients","volume":"61","author":"Tarassoff","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.urolonc.2007.11.004_bib23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2007.11.004_bib24","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2007.11.004_bib25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.urolonc.2007.11.004_bib26","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2007.11.004_bib27","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-\u03baB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814390700261X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814390700261X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:53:48Z","timestamp":1761040428000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814390700261X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S107814390700261X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.11.004","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2007.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}